Survodutide
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
Boehringer Ingelheim · Phase 3 · Completed · Enrollment 5530
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| survodutide 3.6 mg | n/r | n/r | n/r | n/r |
| survodutide 6.0 mg | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- survodutide 3.6 mg: endpoint not reported
- survodutide 6.0 mg: endpoint not reported
- Placebo: endpoint not reported